Prognosis and Complications of Hyperuricemia Patients Undergoing Isolated Coronary Artery Bypass Surgery

Haydar Yasa1,2*

1Evliya Celebi Education and Research Hospital, Health Science University, Turkey
2Batı Anadolu Central Hospital, Turkey

Introduction

Recent studies suggest that high levels of serum uric acid of very early life are a result of the in-utero environment and may lead to elevated blood pressure in adulthood. However, serum uric acid levels can change throughout life. Researchers investigated the effect of serum uric acid levels in childhood on the blood pressure tracking and analysed blood pressure according to changes in serum uric acid levels in early life.

Hyperuricemia is associated with deleterious effects on endothelial dysfunction, oxidative metabolism, platelet adhesiveness, hemorheology, and aggregation. The atherosclerotic plaque contains a considerable amount of uric acid which may increase platelet adhesiveness and potentiate thrombus formation [1].

There is also increasing evidence that elevated serum uric acid levels may predict the development of type 2 diabetes [2].

Despite the association of hyperuricemia with cardiovascular risk factors, it has remained controversial as to whether uric acid is an independent predictor of cardiovascular disease, with many studies in favour [3-7] and others against [8,9].

Serum concentrations of uric acid, the end product of the metabolism of purine compounds, above 7 mg/dL result in hyperuricemia, causally associated with gout as evidenced in randomized clinical trials using urate lowering therapies [9].

One of the major causes of hypertension and negative effects at the same time during childhood is a disease in which the multiplication of those provided in the etiology of Diabetes mellitus is present. It is possible to speculate that the effects of the early onset of the early onset have serious side effects, in particular cardiovascular system, hypertension, kidney function disorder, diabetes mellitus, and calcium turnover problems. There is insufficient study of the effects of Hyperuricemia on coronary bypass surgery. The aim of our study was therefore to assess the operative and short-term prognosis of hyperurisemic who had CABG (coronary artery bypass graft), comparing non-hyeprurisemic patients. The results of this study are expected to enhance our knowledge regarding the role of uric acid level on outcomes of patients with coronary bypass surgery and thus can be use by clinician in determining patient’s prognosis.

Patients and Methods

Patient evaluation was performed by collecting prospective data on patients undergoing CABG at our hospital from March 2012 to May 2017, primary CABG was performed on 86 consecutive patients in the same surgical groups. One senior nurse at the hospital was trained to collect these data using prespecified settings. From this sample, patients who underwent isolated CABG were selected, and this population was then divided into those with hyperurisemia (group I) and those without hyperurisemia (group II).

The excluded criteria; Patients were excluded if they had undergone any othercardiac surgery, Diabetes Mellitus Tip I, II, redo CABG, emergency cases, chronic obstructive lung disease, Left ventricular ejection Fraction ≤ 30%, chronic renal disease, active gout attack and symptomatic patients (blood
Complications, infectious complications, cardiac arrhythmias, bleeding, wound infection and multiple organ failure occurring within 30 days after the surgery. Postoperative uric acid level measured first visit and second visit. Ethical approval for the study was granted by the local research ethics committee. All of these patients gave their appropriate informed consent and were studied under the approval of the institutional review boards.

**Clinical and Uric Acid Data Collection**

Data obtained from the medical records including history taking associated with ischemia symptoms, head to toe physical examination, and laboratory examination. The laboratory examinations include peripheral blood examination, uric acid, blood urea nitrogen (BUN), creatinine, ALT, AST, random blood glucose, electrolyte, lipid profile, cardiac enzyme includes CK-CKMB and troponin T. Other examinations assessed are electrocardiography, chest X-ray, echocardiography, and coronary angiography.

All the hospital’s cardiac surgery teams agreed to provide data for the development of the database. The logistic EuroSCORE was individually calculated for all patients (preoperative risk score) and expressed as the average of the groups.

**Table 1: Preoperative demographics.**

| Patients          | Grup I (n = 42) | Grup II (n = 44) | p value |
|-------------------|----------------|-----------------|---------|
| Male n (%)        | 33 (76.7%)     | 36 (71.5%)      | 0.080 (2) |
| Female n (%)      | 9 (22%)        | 10 (25.3%)      | 0.081 (2) |
| Age mean ± SD     | 67.3 ± 13.46   | 8 ± 14.84       | 0.087 (1) |
| PMI n (%)         | 24 (56.0)      | 23 (52.9)       | 0.039 (2) |
| HLP n (%)         | 65 (84.5)      | 74 (81.4)       | 0.799 (2) |
| HTN n (%)         | 20 (46)        | 16 (34.7)       | 0.044 (2) |
| PAD (non-surgical) n (%) | 8 (%)        | 6 (%)          | 0.043 (2) |
| Atrial fibrillation n (%) | 2 (5.2%) | none | 0.035 (2) |
| Smoking n %       | 18 (40.3%)     | 38 (85%)        | 0.084 (2) |
| Current smoker. n (%) | 15 (35.2%) | 14 (32.3) | < 0.001 (2) |
| Alcohol use n %   | 7.6%           | 8.8%            | 0.671 (2) |
| Serum creatinine mean ± SD | 1.2 ± 0.6 | 1.0 ± 0.9 | < 0.001 (1) |
| BMI (kg/m²) mean ± SD | 24.2 ± 0.923 | 1 ± 1.2 | 0.565 (2) |
| Fibrinogen (mg/dl) mean ± SD | 293 ± 15.4 | 260 ± 12.3 | 0.044 (1) |
| C-rp (mg/dl) mean ± SD | 1.2 ± 0.6 | 0.8 ± 0.6 | 0.034 (1) |

**Preoperative ICA ultrasound**

| ICA velocity (cm/sec) mean ± SD | 160 ± 0 | 140 ± 50 | 0.049 |
| Chronic lung disease. n (%)   | 9 (21.9) | 8 (18.2) | < 0.001 (2) |
| EuroSCORE logistics mean ± SD | 2.3 ± 2.0 | 2.1 ± 2.4 | 0.0087 (3) |

Pearson correlation’s coefficients each pair of variables shown. Asterisk denote significant correlation coefficients (1. P ≤ 0.05, 2. P ≤ 0.01).

HTN: Hypertension; CAD: Surgical coronary artery disease; LMCAD: Left main coronary artery disease; LVEF: Left ventricle ejection fraction; DM: Diabetes mellitus; HLP: Hyperlipoproteinemia; PMI: Previous myocardial infarction. PAD: Peripheral artery disease; BMI: Body mass index; ICA: Internal carotid artery velocity; C-rp: C-reactive protein; SD: Standard deviation.

(1) Descriptive level of probability determined by the Student’s t-test; (2) Descriptive level of probability determined by the chi-square test; (3) Descriptive level of probability determined by the nonparametric Mann-Whitney U test.
Statistical Analysis

Initially, all variables were descriptively analyzed. For quantitative variables, analyses were carried out by observing minimum and maximum values and calculating the mean and standard deviation. For qualitative variables, absolute and relative frequencies were calculated. To compare the averages of the two groups, we used Student’s t-test and when the assumption of data normality was rejected, we used the nonparametric Mann-Whitney U test. To test the homogeneity between proportions, we used the chi-square test or the Fisher’s exact test. Two-sided P values were always computed and differences were considered statistically significant at p ≤ 0.05. All analysis performed using statistical package for social solution (SPSS) software version 17.

Results

The two groups were similar according to clinical characteristics such as age, risk factors, gender, smoking, using alcohol, BMI, previous myocardial infarction, dyslipidemia, Previous cerebrovascular accident, EuroSCORE and history of congestive heart failure (Table 1). There were longer aortic x-clamp time (mean ± SD) and total bypass time (mean ± SD) in group I versus group II. (62 ± 18, 62.1 ± 16.0, p ≤ 0.05) (Table 2). There were found more LMCA in group I versus group II (although this difference did not reach statistical significance, p ≥ 0.05), and group I patients were more likely to have had manifestation of coronary artery disease (mean ± SD) (3.15 ± 1.6 versus 2.8 ± 1.4, p ≤ 0.05) and to have significant internal carotid artery velocity more than group I to group II ((cm/sec) mean ± SD) 160 ± 60 versus 140 ± 50, p ≤ 0.05), although this difference was no longer significant when only the rate of previous stroke or TIA was considered and carotid artery occlusion (only ICA velocity) Table 1. Group I also had a trend toward higher prevalence of significant left ventricular dysfunction (LVEF mean ± SD 45.8 ± 13.65 versus 48.9 ± 11.43 p ≤ 0.05). Coronary artery lesions have more affected Group I than Group II and number of coronary artery disease have more Group I rather than Group II (Table 3). Coronary angiographic have been evaluating Group C lesions more affected group I than group II (p ≤ 0.05) (Table 3). There haven’t seen mediastinitis in two groups. There have wound infections in 3 patients group I and 2 patients in Group II but there haven’t statistical differrentation. These have wounded infection limitation area (3 patients have safen insizyon line, 1 patient sternal mediastinal area and one patient thorax tube line). All of the patients have heeling after 2 weeks postoperative period (Table 2).

Table 2: Operative variables results.

| Variables                              | Group I (n = 42) | Group II (n = 46) | p value |
|----------------------------------------|-----------------|------------------|--------|
| CPB time (min) ± SD                    | 55 ± 18.3       | 50 ± 21          | 0.043  |
| Cross-clamp time (min) ± SD            | 23.1 ± 16.0     | 22 ± 18          | 0.034  |
| Time spent in the intensive care unit ± SD | 1.6 ± 0.9       | 1.6 ± 1.4        | ns (4) |
| Prolonged mechanical ventilation n.%   | 1 (2.3)         | none             | 0.806  (1) |
| Orotracheal reintubation during hosp.n. % | 1 (2.3)         | none             | < 0.001 (2) |
| Readmission to the intensive care unit n.% | 1 (2.3)         | 1 (2.1)          | 0.856  (2) |
| Bleeding chest tubes (mL) ± SD         | 450 ± 280       | 430 ± 260        | 0.032  (4) |
| Time of hospitalization (days) ± SD    | 5.9 ± 8.7       | 5.8 ± 7.6        | 0.088  (4) |
| Cerebrovascular accident. n. (%)       | 1 (0.5)         | none             | 0.623  (3) |
| Acute renal failure n. (%)             | 1 (0.9)         | none             | 1.000  (3) |
| Cell saver (ml) ± SD                   | 135.1 ± 291     | 95.3 ± 221       | 0.001  (2) |
| Packed red                             | 1.5 ± 1.9       | 1.9 ± 2.0        | < 0.001 (2) |
| Use of fresh frozen plasma 172 (7.9)   | 85 (10.8)       | 87 (6.2)         | < 0.001 (2) |
| Use of platelet concentrae             | 56.7 (7.1)      | 51 (3.6)         | < 0.001 (2) |
| Dialysis n. (%)                        | 1 (0.5)         | none             | (3)    |
| Infections (wound)n. (%)               | 3 (6.5)         | 2 (7.4)          | 0.705  (2) |
| Mediastinitis n. (%)                   | none            | none             | (3)    |
| Urinary tract infection                | none            | none             | (3)    |
| Pneumonia                              | none            | none             | (3)    |
| Arrhythmia n. (%)                      | 7 (14.9)        | 8 (14.4)         | 0.892  (2) |
| Intraoperative death                   | none            | none             | (3)    |
| Death within 30 days                   | none            | none             | (3)    |

(1) Descriptive level of probability by the Student’s t-test; (2) Descriptive level of probability by the chi-square test; (3) Descriptive level of probability by the Fisher’s exact test; (4) Descriptive level of probability by the nonparametric Mann-Whitney U-test.
In relation to medical treatment, hyperuricemia had the highest rates of previous use of medications such as calcium-channel blockers (21.5% of patients with Group I vs. 17.6% of Group II patients; \( P = 0.043 \)), angiotensin-converting enzyme inhibitors (52.6% of patients with Group I vs. 47.4% of Group II; \( P = 0.038 \)) and angiotensin II receptor blockers (20.4% of patients with Group I vs. 15.0% of Group II; \( P = 0.048 \)).

### Discussion

Gout is a painful inflammatory arthritis which can eventually lead to the decrease in quality of life [11]. It is also a risk factor for mortality and cardiovascular morbidity [12]. The prevalence is reported to be increasing in many countries. In the USA the figure reached as much as 3.9% (8.3 million inhabitants) during 2007-2008 [8]. Gout afflicts approximately 2% of men older than 30-years and 2% of women older than 50-years, and is the most common form of inflammatory joint disease in men older than 40-years. Serum uric levels are, on average, 0.5 to 1.0 mg/dL higher in men than women, making male sex a risk factor for hyperuricemia and gout. Lower serum uric levels in women are associated with the presence of estrogen, which is thought to act as an antihyperuricemic factor [13].

The enzyme, xanthine oxidase, which is present in significant levels only in the liver and intestine, oxidizes hypoxanthine and xanthine to uric acid in the purine catabolic pathway. Xanthin oxidase inhibitors could be used clinically to block the final step in uric acid synthesis, thereby reducing the production of uric acid.

To our knowledge, this is the first studies in a cohort coronary bypass surgery patients admitted to assess whether high uric acid levels at admission might increase risk for major adverse cardiac events during hospitalization, operation variables, using survival approach to describe and analyze the free survivals between hyperurisemic and normouricemic groups.

One study, in 58 patients undergoing complicated cardiac surgery, found that preoperative uric acid > 6.0 mg/dL was associated with a nearly 4-fold increased risk of Akut kidney injury (AKI) and a longer hospital stay than preoperative uric acid ≤ 6.0 mg/dL [14]. Another study, in 190 patients undergoing cardiovascular surgery, found that, after adjustment for confounders by multivariate logistic regression analysis, serum uric acid concentrations ≥ 7.0 mg/dL were associated with a 35-fold higher risk of AKI, and increased hospital stay and duration of mechanical ventilation support, than serum uric acid concentrations < 7.0 mg/dL [15]. Our previous study in patients undergoing cardiovascular surgery also found that preoperative hyperuricemia was an independent risk factor of postoperative AKI and was related to poor outcomes [16]. Our findings are in agreement with those of the above studies. At the same time intubation time, the proportion of re-intubation time, time spent in the intensive care, prolonged mechanical ventilation orotracheal reintubation during hospitalization, readmission to the intensive care unit more Group I than Group II. However, no statistical difference was found between the reasons for the low number of cases.

It is very well known that there are certain risk factors such as genetic susceptibility, hypertension, hyperlipidemia, smoking, and diabetes mellitus, which may predispose an individual to coronary artery disease. Additionally, hyperhomocysteinemia and metabolic syndromes have been identified as other risk factors for the disease as well as predictors of the success of the treatment and survival of the patients [11]. Recently, elevated serum uric acid level is identified as an independent risk factor for cardiovascular diseases [13-19]. Several prospective studies have shown an association between hyperuricemia and cardiovascular diseases and death [1,11-13,15,16]. In this study, the number of coronary artery involvement in hyperuricemic patients and Type C lesion in coronary arteries were statistically significant. Asymptomatic long-term follow-up of hyperuricemia is considered to be a factor in this issue. Interestingly, more prevalence of carotid artery disease was observed. Carotid artery disease was not included in this study because of isolated coronary bypass surgery cases. However, velocity flow rates in the USG of pre-operative carotid doppler were higher in group I.

Hyperurisemia patients present an increased risk for postoperative infections due to depreciated host defense mechanisms, such as impaired as wound healing and granulocyte function, decreased cellular immunity, impaired complement function, and reduced immune response, which may be influenced by the gout control [3-6].

Another issue is the investigation of hyperuricemia on postoperative bleeding and on the coagulation cascade. In this study, postoperative bleeding rates, red packed and use of fresh frozen were found to be higher in the hyperuricemic group.

The effects of hyperuricemia on kidney function, hypertension and vascular structure are known. The group was mostly bypassed and had a longer lesion length. These noted effects were effective on postoperative bleeding. However, we believe that this issue needs further investigation.

### Table 3: Preoperative angiographic characteristics.

| Coronary lesions. (AHA classification) | Group I | Group II | \( p \) Value |
|--------------------------------------|---------|----------|--------------|
| Type A                               | 8       | 12       | NS           |
| Type B                               | 20      | 21       | NS           |
| Type C                               | 14      | 11       | 0.012        |
| Single vessel                        | 10      | 14       | 0.023        |
| Double vessel                        | 14      | 16       | NS           |
| Triple vessel                        | 18      | 14       | NS           |

Left main coronary artery

| Disease                              | 1       | 4        | 0.011       |
|--------------------------------------|---------|----------|-------------|
| Ejection fraction                    | (mean ± SD) [%] | 43 ± 10.4 | 45 ± 11.7 | NS |
| Significant left ventricular dysfunction | 25      | 22       | 0.031       |

AHA: American Heart Association; NS: Not significant.
Another issue is the question of postoperative use of acet- 
yl salicylic acid. As is known, the use of anti-aging is essential 
after coronary bypass surgery. Otherwise Low-dose asetyl- 
salicylic acid can precipitate gout attacks. In this case, it is 
necessary to use clopidogrel, which is another antiagregan 
in place of acetysalicylic acid. However, the correlation be-
tween clopidogrel and hyperuricemia is not well researched. 
In this respect, it is also necessary to decide on the study 
and the application of an antiagregan protocol in postoperative 
hyperuricemic patients.

Additionally, Gout is more common after surgery, trauma, 
and dehydration. Certain medications such as diuretics (com-
monly known as water pills), which treat high blood pressure, 
that raise the level of uric acid in the bloodstream are risks 
for gout. For this reason, the hyperuricemic values of patients 
receiving surgery should be closely monitored. In this study, 
blood uric acid levels of all patients after the early period 
were routinely monitored and, if necessary, patients were di-
rected to rheumatology.

Foods and drinks that contribute most to hyperuricemia 
and gout include: Red meat, organ meat, seafood, beer, li-
quor, and sugar-sweetened items, especially with high fruc-
tose corn syrup. Hyperuricemic diet has been applied in all of 
your patients and diets have been adjusted by dieticians. As a 
result of this study, all cardiovascular and cardiologists should 
be more sensitive about hyperuricemic diet.

Health problems such as obesity, high blood pressure, 
high blood sugar, and high cholesterol may also lead to in-
creased uric acid and the development of gout. And because 
some medications may also increase risk. Other causes of 
hyperuricemia and gout include kidney disease, exposure to 
lead, hypothyroidism, severe illness or stress, and extreme 
physical exertion.

As a result, hyperuricemia seems to be an issue that does 
not stop at all. Hyperuricemia, which has effects on kidney, 
lever, coronary vessels, carotid and other peripheral vessels, 
should be considered a metabolic disease, such as a Diabetes 
Mellitus. Patients with close follow-up and treatment should 
be informed about possible effects of hyperuricemia. We be-
lieve that there should be an entity that should be empha-
sized especially in terms of cardiovascular surgery.

Disclosure

The authors have no conflicts of interest to disclose.

Authors Contribution

Conception & design of the study. Yasa H. Acquisition 
of data: Interpretation and analysis of the data, Writing the 
draft and paper: Yasa H. Agree with manuscript results and 
conclusions: H.Yasa, Review and approval of final manuscript: 
H.Yasa.

References

1. Leyva F, Anker S, Swan JW, et al. (1997) Serum uric acid as an 
index of impaired oxidative metabolism in chronic heart failure. 
Eur Heart J 18: 858-865.
2. Kodama S, Saito K, Yachi Y, et al. (2009) Association between 
serum uric acid and development of type 2 diabetes. Diabetes 
Care 32: 1737-1742.
3. Nagahama K, Iseki K, Inoue T, et al. (2004) Hyperuricemia and 
cardiovascular risk factor clustering in a screened cohort in Oki-
nawa, Japan. Hypertens Res 27: 227-233.
4. Krishnan E, Baker JF, Furst DE, et al. (2006) Gout and the risk of 
acute myocardial infarction. Arthritis Rheum 54: 2688-2696.
5. Ejaz AA, Beaver TM, Shimada M, et al. (2009) Uric acid: A novel 
risk factor for acute kidney injury in high-risk cardiac surgery pa-
tients? Am J Nephrol 30: 425-429.
6. Lapsia V, Johnson RJ, Dass B, et al. (2012) Elevated uric acid in-
creases the risk for acute kidney injury. Am J Med 125: e9-e17.
7. Joung KW, Jo JY, Kim WJ, et al. (2014) Association of preopera-
tive uric acid and acute kidney injury following cardiovascular 
surgery. Journal of Cardiothoracic and Vascular Anesthesia 28: 
1440-1447.
8. Zhu Y, Pandya BJ, Choi HK (2011) Prevalence of gout and hyper-
uricemia in the US general population: The National Health and 
Nutrition Examination Survey 2007-2008. Arthritis Rheum 63: 
3136-3141.
9. Culleton BF, Larson MG, Kannel WB, et al. (1999) Serum uric acid 
and risk for cardiovascular disease and death: The Framingham 
Heart Study. Ann Intern Med 131: 7-13.
10. Fang J, Alderman MH (2000) Serum uric acid and cardiovascular 
mortality the NHANES I epidemiologic follow-up study, 1971-
1992. National Health and Nutrition Examination Survey. JAMA 
283: 2404-2410.
11. Tavil Y, Sen N, Hizal F, et al. (2008) Relationship between elevat-
ed levels of serum uric acid and saphenous vein graft disease. 
Turk Kardiyol Dern Ars 36: 14-18.
12. Suarna C, Dean RT, May J, et al. (1995) Human atherosclerotic 
plaque contains both oxidized lipids and relatively large amounts 
of alpha-tocopherol and ascorbate. Arteriosclerosis, Thrombo-
sis, and Vascular Biology 15: 1616-1624.
13. Alderman MH, Cohen H, Madhavan S, et al. (1999) Serum uric 
acid and cardiovascular events in successfully treated hyperten-
sive patients. Hypertension 34: 144-150.
14. Bos MJ, Koudstaal PJ, Hofman A, et al. (2006) Uric acid is a risk 
factor for myocardial infarction and stroke: The Rotterdam 
Stroke 37: 1503-1507.
15. Tayar JH, Lopez-Olivo MA, Suarez-Almazor ME (2012) Febux-
ostat for treating chronic gout. Cochrane Database Syst Rev 11.
16. Rathman W, Funkhouser E, Dyer AR, et al. (1998) Relations of 
hyperuricemia with the various components of the insulin resis-
tance syndrome in young black and white adults: The CARDIA 
Study. Ann Epidemiol 8: 250-261.
17. Krishnan E, Kwok K, Schumacher R, et al. (2007) Hyperuricemia 
and the incidence of hypertension among men without metabolic 
syndrome. Hypertension 49: 298-303.
18. Leibovic L, Yehezkieli Y, Porter A, et al. (1996) Influence of di-
betes mellitus and glycaemic control on the characteristics and 
outcome of common infections. Diabet Med 13: 457-463.
19. Wallace KL, Riedel A, Ridge NJ, et al. (2004) Increasing prevalence 
of gout and hyperuricemia over 10 years among older adults in a 
managed care population. J Rheumatol 31: 1582-1587.